CClinicalTrials.gg
CompletedNCT03445312SalientUpdated Jun 1, 2020

Safety and Effectiveness of a Laboratory Intervention to Effectively NOT Treat Asymptomatic Bacteriuria

An observational study in Asymptomatic Bacteriuria and Urinary Tract Infections, sponsored by Mount Sinai Hospital, Canada. Completed at 1 site in Canada. Per ClinicalTrials.gov, last updated 2020-06-01.

Sponsored by Mount Sinai Hospital, Canada · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,394
Sex
All
01

Study summary

This is an observational cohort study of 1000 consecutive patients on medical and surgical wards at the Mount Sinai Hospital in Toronto who have a mid-stream urine culture ordered. When these cultures are ordered or received in the laboratory, a message is posted that the specimen will not be processed in the laboratory unless a call is received to say that the patient has local urinary symptoms. The goal is to establish whether not processing mid-stream urine cultures is safe.

Read the detailed description

The clinical information system for Mount Sinai Hospital will be programmed such that, whenever a mid-stream urine sample is received in the microbiology laboratory from medical and surgical wards, the specimen will be held rather than processed. The system will reflex a result the specimen (either at a set time twice daily, or at the time the specimen is accessioned) with a message saying: "The great majority of positive urine cultures from inpatients without an indwelling urinary catheter represent asymptomatic bacteriuria and are no longer routinely processed. If you strongly suspect that your patient has developed a urinary tract infection or if you have mislabeled this specimen, please call the Microbiology laboratory within 48 hours to request processing of this urine culture".

Any urine being held in the microbiology laboratory will automatically generate an email alert to the study coordinator. Within 24 hours of receipt of the urine culture, the coordinator will confirm that the specimen was a midstream urine specimen, interview the patient, determine if they have had any symptoms of a urinary tract infection, and collect information on what other symptoms of infection were present when the culture was ordered, why the culture was ordered, and whether antibiotic therapy was started empirically.

All patients whose urines have not been processed will have a second follow-up visit/call at 72-96 hours to ensure that urinary symptoms have not developed or worsened. If symptoms develop/worsen, the study coordinator will have the investigator follow up.

All patients will have a follow-up telephone call/visit 28-35 days after the specimen is obtained to identify any intercurrent infections (including C. difficile infection), and any potential complications/adverse effects from antibiotics. Permission will be obtained to contact family or other attending physicians to clarify any information if necessary.

Data collected for each patient will include: age, gender, underlying medical conditions, reason for hospitalization, date of admission to hospital, service at admission and at the time urine specimen obtained, date urine specimen obtained, whether or not urine culture processed, urine culture results and date reported (if the urine culture was processed), urinalysis results (if ordered), why the urine culture was ordered, whether the patient had fever, hypothermia, dysuria, urgency, frequency, costophrenic angle tenderness, increased incontinence, presence/absence of delirium, presence/absence of any other behavior changes, whether the patient was capable of reporting urinary tract symptoms, duration of each symptom, whether or not empiric antibiotics were ordered (name, dose, duration) at the time the specimen was ordered and what the indication for antibiotics was, what the whether or not antibiotics ordered empirically were stopped if the urine culture was reported as negative; whether empiric antibiotics were appropriate to the pathogen (if the urine was cultured), whether the antibiotic regimen was changed in response to culture results (urine or other); what the final diagnosis from the most responsible physician was regarding the episode for which the urine culture was ordered; whether the episode met NHSN criteria for any infection, whether the patient developed any adverse events potentially associated with antibiotics (includes solicited: nausea, vomiting, diarrhea (including CDI), rash, vaginitis, any allergic reaction) and unsolicited - if the unsolicited are known to be adverse events associated with the antibiotic in question (eg. Stevens-Johnson syndrome with Septra, achilles tendon rupture with fluoroquinolones). Data will be collected by chart review, and by interview with the patient/next of kin.

For each patient in whom a serious adverse event occurs, a case summary will be prepared. Based on the case summary, hospital chart, and study notes, two internists/infectious disease physicians, otherwise unrelated to the study will be asked independently to assess whether the serious adverse event was associated with the failure to process a urine culture (if one was not processed), or associated with antibiotic prescribed for asymptomatic bacteruria. If the two physicians disagree, a third physician will review, and the three will meet to arrive at a consensus. If consensus cannot be achieved, the event will be recorded as associated with not performing the culture or with the antibiotic if 2 physicians of the 3 agree.

02

Conditions studied

  • Asymptomatic Bacteriuria
  • Urinary Tract Infections
03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All inpatients on medical and surgical units who have a mid-stream urine culture ordered

Inclusion criteria

  • inpatients on medical or surgical units at Mount Sinai Hospital

Exclusion criteria

Exclusion Criteria:

  • none
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,394 participants (actual)
Patient registry
No

Groups and cohorts

  • study cohort

    All non-ICU medicine and surgery patients at Sinai Health System who have a mid-stream urine culture ordered

    Behavioral: not processing urine cultures

Interventions

  • Behavioralnot processing urine cultures

    microbiology lab will not process culture unless called

05

What researchers measure

Primary outcomes

  1. serious adverse events (SAE) associated with not processing urine culture

    serious adverse events associated with not processing urine culture

    Time frame: 30 days

Secondary outcomes

  1. Differences in SAE

    Rate of serious adverse events in patients without symptoms who did and did not have urine specimens processed

    Time frame: 30 days

  2. SAE due to antibiotics

    Rate of serious adverse events due to antibiotic therapy in patients who received antibiotics for asymptomatic bacteriuria

    Time frame: 30 days

  3. Non-response

    Proportion of patients with symptomatic urinary tract infection (UTI) who did not respond to initial empiric antibiotics

    Time frame: 4 days

06

Study locations

1 site
  • Mount Sinai Hospital
    Toronto, Ontario M5G 1X5, Canada
07

References and documents

Individual participant data

Plan to share: No — individual patient data will not be available to other researchers. This is a quality improvement study

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03445312
Lead sponsor
Mount Sinai Hospital, Canada
Responsible party
Allison McGeer (Medical Director, Infection Prevention and Control, Mount Sinai Hospital, Canada) — Principal investigator
First posted
Feb 26, 2018
Start date
Aug 31, 2017
Primary completion
May 15, 2019
Completion
Nov 15, 2019
Last update
Jun 1, 2020

Study contacts

Allison McGeer
principal investigator · Sinai Health System

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion